Where Are SPY and QQQ Headed? Here's What I Can Offer Now

Real Money subscribers are asking good questions. Let's tackle them together.

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

I like these names as stand-alone entities but they should also attract interest from larger players.

Any Bounce in This Nasty Bear Market Should Be Viewed With Caution

For now, any rebound is a short-term trading opportunity and nothing more.

Psst, Here's a 'TIP' for You: An ETF That Performs Well Amid Inflation

The Proshares Inflation Expectations exchange-traded fund appears more than a Treasury Inflation-Protected-focused product.

Trading for a Bounce -- Not a Bottom

Here's my thinking on the Nasdaq, bonds, energy, commodities and crypto right now.

If You Insist on Trading This Brutal Market, Don't Get Lazy With Your Stops

That word of warning applies to ETFs and individual stocks such as Intercept Pharmaceuticals, which we outline a trading strategy for here.

Let's Pick Through the Carnage in the Biotech Sector for Ways to Play It

An ETF provides one opportunity, as do a few individual stocks.

Index Road Kill, S&P 500 Has a Pulse, Sector Slaughter, Betting on CEOs

Plus, we take a revealing look at the movements in the yield curve and pop in on the dismal charts of Shopify and Peloton Interactive.

If You're Fearful of Stagflation, This Brand-New ETF Could Be for You

Launched just this week, the Merk Stagflation ETF is a fund-of-funds that focuses on four asset classes.

The MOAT ETF Could Float Your Boat If You Desire Good Relative Performance

The VanEck Morningstar Wide Moat ETF has held its own against the SPDR S&P 500 ETF and diversified giant Berkshire Hathaway.